Publications

Nature reviews. Clinical oncology

From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer.

15-12-2025

CA: a cancer journal for clinicians

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

13-12-2025

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

20-11-2025

International journal of radiation oncology, biology, physics

Health-Related Quality of Life in Patients Treated for Nonmetastatic Muscle-Invasive Bladder Cancer: Radical Cystectomy Versus Bladder-Preserving Therapy.

15-11-2025

European journal of cancer (Oxford, England : 1990)

Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.

16-10-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.

01-10-2025

European urology

Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.

01-10-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.

15-09-2025

Immuno-oncology technology

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

01-09-2025

ESMO open

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

01-08-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

The Lancet. Oncology

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.

01-06-2025

Nature cancer

The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.